-
01:11:48 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

AZN Stock News

05/15/22 1:24 PM
Nasdaq : AZN
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
It is being developed by AstraZeneca and Avillion. A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma. Available at https://clinicaltrials.gov/ct2/show/NCT03847896.. AstraZeneca Pharmaceuticals.
RHEA-AI
negative
05/05/22 7:05 AM
Nasdaq : AZN
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
High-level results from the DELIVER Phase III trial showed AstraZeneca’ s FARXIGA reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular death or worsening heart failure. The trial was conducted in patients with HF with mildly reduced or preserved ejection fraction.
RHEA-AI
neutral
05/05/22 7:00 AM
Nasdaq : AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
AstraZeneca and Daiichi Sankyo’ s ENHERTU ® has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six...
RHEA-AI
neutral
05/05/22 7:00 AM
Nasdaq : AZN
ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that ULTOMIRIS ® achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder compared to the external placebo arm from the pivotal...
RHEA-AI
negative
05/04/22 8:00 AM
Nasdaq : AZN
Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
The Food and Drug Administration grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. 1 The Prescription Drug User Fee Act date, the FDA action date for their...
RHEA-AI
negative